{"name":"Cardiol Therapeutics","slug":"cardiol","ticker":"CRDL","exchange":"NASDAQ","domain":"cardiolrx.com","description":"Cardiol Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cardiovascular disease. The company's lead product, CardiolRx, is an anti-inflammatory treatment for heart failure. Cardiol Therapeutics is positioned to address the significant unmet medical need in heart failure, a leading cause of morbidity and mortality worldwide.","hq":"Oakville, Ontario, Canada","founded":0,"employees":"","ceo":"David Elsley","sector":"Anti-inflammatory / Cardiovascular","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CardiolRx","genericName":"CardiolRx","slug":"cardiolrx","indication":"Acute myocardial infarction with reduced ejection fraction","status":"phase_3"}]}],"pipeline":[{"name":"CardiolRx","genericName":"CardiolRx","slug":"cardiolrx","phase":"phase_3","mechanism":"CardiolRx is a cardiac-regenerative therapy designed to repair and restore heart function following myocardial injury.","indications":["Acute myocardial infarction with reduced ejection fraction","Heart failure with reduced ejection fraction"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Cardiol Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Cardiol Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical development programs and commercialization efforts.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Cardiol Therapeutics Announces Strategic Partnership with a Leading Pharmaceutical Company","summary":"Cardiol Therapeutics entered into a strategic partnership with a leading pharmaceutical company to accelerate the development and commercialization of its lead product, CardiolRx.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"trial","headline":"Cardiol Therapeutics Announces Positive Topline Results from Phase 2 Clinical Trial of CardiolRx","summary":"Cardiol Therapeutics announced positive topline results from its Phase 2 clinical trial of CardiolRx, demonstrating its potential as a treatment for heart failure.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNUmNOOHlwRlNTbUVHYmJxWWxSVnQxWVVqcWc4SFhjSjJ1UUJaT0dNcG5nNmpBVkcyMjA3X2FBbEh2RjR5RU84V0w5YXBCalYyaUtyRWpZU2RfNkZMcjJWQThCRWVXRUxSQkwzbnBKWlJtSkttYW9XVnNHTDRLVlBzSFlXVXZHMC04U0ZYdk85RDUwRDhBWDhKTEViOGVvdExUY3N6dzR3SGdERmliWGlPR01uQlVFSXhQeF9EZHAzc3VRelpjeUl3Q1FQV19ZdGZ6MTd5Mg?oc=5","date":"2026-04-01","type":"earnings","source":"MarketBeat","summary":"Cardiol Therapeutics (NASDAQ:CRDL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat","headline":"Cardiol Therapeutics (NASDAQ:CRDL) Posts Earnings Results, Beats Expectations By $0.04 EPS","sentiment":"positive"},{"date":"2026-04-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQUTNIcXZHR3RpOWlvQ19ybkdhbmFpaE96YXV1ekFUeC1FVDJ5eGU5TEZsS2lubG9hem9XQktNVmQ3cTBXY1kyQkFMOF9HWHRQc3J0NjU0OG1CYnp5dk1JalRIcXgtWENwZHlHdTZxSVM1NlU3S0EtWE9PeUlvVTJWWmlQY01tQ052WmlyNUlLQmVxa2oyemlIUHNMUG02cnYwSG44MkdLZmNCZXROYlZ5WUdvT0pUbFBNNDBJN2V5VnhvSFBtMDc1UzJneE4?oc=5","date":"2026-03-25","type":"earnings","source":"MarketBeat","summary":"Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat","headline":"Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday","sentiment":"positive"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-02-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-26","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-16","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-01-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOTW1hcHZDMzN4dEU1TmNEcFJ0cnZsMVo3eUJONmZxMWoyM1BsWXlzUEdDRFQ1RjktMy0xRVdXcWJKWXJmSzE3RmgtYnhSaGhNYVRkWC10QVZLOU9WMVo5ekxHZUlBUkIydlRwSndKOVZVbUhTSnI0RzMxR1pucldmX1BvbnlHdjV0NXVTYnJnU0thdGNHMUJZ?oc=5","date":"2026-01-12","type":"pipeline","source":"Yahoo Finance","summary":"Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long - Yahoo Finance","headline":"Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long","sentiment":"neutral"},{"date":"2025-12-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bristol Myers Squibb","Pfizer"],"therapeuticFocus":["Anti-inflammatory","Cardiovascular"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}